Comparison of Callisphere Drug-Eluting Beads Transarterial Chemoembolization and Conventional Transarterial Chemoembolization for the treatment of Hepatocellular Carcinoma.

OBJECTIVE

To compare the efficacy of CalliSphere drug-eluting beads (DEBs) and conventional (c) transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC).

METHODS

We retrospectively reviewed the clinical data of 125 patients with HCC who had received treatment in Affiliated Hospital of North Sichuan Medical College from January 2018 to February 2019. Sixty-one patients underwent DEB-TACE (observation group) and 64 patients underwent cTACE (control group). The clinical efficacies, overall survivals, and incidence of postoperative adverse reactions between the two groups were compared.

RESULTS

The objective response rate in the observation group (85.25%) was higher than that in the control group (70.31%; <0.05). The disease control in the observation group (96.72%) was higher than that in the control group (85.94%; <0.05). The median survival time of the observation group (24.85 months) was significantly higher than that in the control group (18.18 months; <0.05). The incidence of adverse reactions in the observation group (4.92%) was lower than that in the control group (17.19%, <0.05).

CONCLUSIONS

In the treatment of HCC, Callisphere DEB-TACE has better efficacy and longer patient survival with fewer adverse reactions compared to cTACE.